ARDS / Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design

Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301. more_horizontal

Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a more_horizontal

Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment more_horizontal

Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of ca more_horizontal

Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis. more_horizontal

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do t more_horizontal

The stock price of Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) increased by over 30% during intraday trading today. This is why it happened. more_horizontal

The stock price of Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) increased by over 30% during intraday trading today. This is why it happened. more_horizontal